Common Misdiagnoses During the Workup of Inherited Channelopathies
Abstract Body (Do not enter title and authors here): Background: Cardiac channelopathies are a heterogenous group of genetic heart diseases (GHDs) that affect cardiac ion channel function. The most prevalent among these are long QT syndrome (LQTS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) which predispose patients to potentially life threatening ventricular arrhythmias. Accurate and timely diagnosis is important for the management and risk stratification of the index case and identification of potentially at-risk relatives. Unfortunately, despite rising awareness of these GHDs, critical warning signs are overlooked.
Objective: To describe the phenotypes of patients who present with a delayed or missed diagnosis of LQTS or CPVT.
Methods: EMR data was reviewed for all patients evaluated and treated at Mayo Clinic between 2000-2023 who arrived with a mis- or delayed diagnosis of LQTS or CPVT. Data was abstracted for patient demographics, clinical characteristics, family history of SCD, and cardiac and genetic test results.
Results: Overall, 47/2119 (2%) patients [33 (70%) female, mean age at correct diagnosis 26±18 years] diagnosed with LQTS (30; 2% of LQTS cohort) or CPVT (17; 7% of CPVT cohort) arrived with an outside misdiagnosis (37, 79%) or underdiagnosis (10, 21%). The most common misdiagnosis was epilepsy (20; 43%) or vasovagal syncope (14; 30%) and 3 CPVT patients (6%) were misdiagnosed with LQTS. Of the 10 underdiagnosed patients, 4 (40%) had QT prolongation, 4 (40%) family history of SCD, 3 (30%) bilateral deafness, and 1 (10%) fetal bradycardia and syndactyly. Overall, 40/47 (85%) were symptomatic (syncope: 29 [73%], seizures: 21 [53%], SCA: 10 [25%]) prior to diagnosis. Of note, 34/40 (85%) had symptoms with exertion, 5 (13%) at rest, and trigger was unknown in 1 (2%). Of the 7 asymptomatic patients (15%), 4 (57%) had QT prolongation and 4 (57%) had family history of SCD. In total, 20/47 patients (43%) had positive family history of SCD under 45 years of age. Overall, patients experienced a median delay in diagnosis of 8 years during which a median of 4 events (range: 1-150) occurred. As a result, an additional 29 family members of these patients received a delay in their diagnosis.
Conclusions: Recognizing the signs and symptoms of patients with GHDs is important to reduce the ongoing burden of misdiagnosis or delayed diagnosis in LQTS and CPVT. The most important factors for suspicion of an inherited channelopathy are symptoms during exertion and family history of SCD.
Bains, Sahej
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Neves, Raquel
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Bos, Johan
( Mayo Clinic College of Medicine
, Rochester
, Minnesota
, United States
)
Giudicessi, John
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Ackerman, Michael
( Mayo Clinic
, Rochester
, Minnesota
, United States
)
Author Disclosures:
Sahej Bains:DO NOT have relevant financial relationships
| Raquel Neves:DO NOT have relevant financial relationships
| Johan Bos:DO NOT have relevant financial relationships
| John Giudicessi:DO have relevant financial relationships
;
Consultant:Avidity Biosciences:Active (exists now)
; Other (please indicate in the box next to the company name):Prolaio (equity/royalty sharing):Active (exists now)
; Research Funding (PI or named investigator):Tenaya Therapeutics:Active (exists now)
| Michael Ackerman:DO have relevant financial relationships
;
Consultant:Abbott:Active (exists now)
; Royalties/Patent Beneficiary:Thryv Therapeutics:Active (exists now)
; Royalties/Patent Beneficiary:Pfizer:Past (completed)
; Royalties/Patent Beneficiary:ARMGO Pharma:Active (exists now)
; Royalties/Patent Beneficiary:Anumana:Active (exists now)
; Royalties/Patent Beneficiary:AliveCor:Active (exists now)
; Consultant:Tenaya Therapeutics:Active (exists now)
; Consultant:Solid Biosciences:Active (exists now)
; Consultant:Medtronic:Active (exists now)
; Consultant:Invitae:Active (exists now)
; Consultant:Illumina:Active (exists now)
; Consultant:Daiichi Sankyo:Past (completed)
; Consultant:Bristol Myers Squibb:Active (exists now)
; Consultant:Boston Scientific:Active (exists now)
; Consultant:BioMarin Pharmaceutical:Active (exists now)